Skip to main content
SpringerLink
Log in

Molecular Genetics of Tumors of the Central Nervous System

  • Chapter
Brain Tumors

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

1985 marked the first reporting of a specific gene alteration in a human central nervous system (CNS) tumor: epidermal growth factor receptor (EGFR) gene amplification in glioblastoma (43). Since that time, a relatively short period by most standards, neuro-oncology research has revealed many genetic abnormalities that indicate consistent genotype-phenotype associations for the various cancers that are collectively referred to as CNS tumors. This chapter reviews the established CNS tumor genotype associations, and discusses resulting molecular biologic consequences as well as the clinical implications of these genetic alterations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahrendt S.A., Halachmi S., Chow J.T., et al. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA 96:7382–7387.

    Article  PubMed  CAS  Google Scholar 

  2. Bello M.J., Vaquero J., de Campos J.M., et al. 1994. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int. J. Cancer 57:172–175.

    Article  PubMed  CAS  Google Scholar 

  3. Bigner S.H., Mark J., Burger P.C., et al. 1988. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48:405–411.

    PubMed  CAS  Google Scholar 

  4. Bigner S.H. Wong A.J., Mark J., et al. 1987. Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet. Cytogenet. 29:165–170.

    Article  PubMed  CAS  Google Scholar 

  5. Bogler O., Huang H.J., Cavenee W.K. 1995. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res. 55:2746–2751.

    PubMed  CAS  Google Scholar 

  6. Brown P.O., Botstein D. 1999. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21:33–37.

    Article  PubMed  CAS  Google Scholar 

  7. Cairncross J.G., Ueki K., Zlatescu M.C., et al. 1998. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90:1473–1479.

    Article  PubMed  CAS  Google Scholar 

  8. Cantley L.C., Neel B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96:4240–4245.

    Article  PubMed  CAS  Google Scholar 

  9. Decker H.J., Weidt E.J., Brieger J. 1997. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet. Cytogenet. 93: 74–83.

    Article  PubMed  CAS  Google Scholar 

  10. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:2540–2551.

    Article  PubMed  Google Scholar 

  11. Duan D.R., Pause A., Burgess W.H., et al. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406.

    Article  PubMed  CAS  Google Scholar 

  12. Ekstrand A.J., James C.D., Cavenee W.K., et al. 1991. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:2164–2172.

    PubMed  CAS  Google Scholar 

  13. Ekstrand A.J., Liu L., He J., et al. 1995. Altered subcellular location of an activated and tumour-associated epidermal growth factor receptor. Oncogene 10:1455–1460.

    PubMed  CAS  Google Scholar 

  14. Ekstrand A.J., Longo N., Hamid M.L., et al. 1994. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313–2320.

    PubMed  CAS  Google Scholar 

  15. el-Deiry W.S., Harper J.W., O’Connor P.M., et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169–1174.

    PubMed  CAS  Google Scholar 

  16. Feldkamp M.M., Lala P., Lau N., Roncari L., Guha A. 1999. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurg. 45:1442–1453.

    Article  CAS  Google Scholar 

  17. Feldkamp M.M., Lau N., Rak J., et al. 1999. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81:118–124.

    Article  PubMed  CAS  Google Scholar 

  18. Ferrante K., Winograd B., Canetta R. 1999. Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol. 43:S61–68.

    Article  PubMed  CAS  Google Scholar 

  19. Fischer U., Muller H.W., Sattler H.P., et al. 1995. Amplification of the MET gene in glioma. Genes Chromosom. Cancer 12:63–65.

    Article  PubMed  CAS  Google Scholar 

  20. Frederick L., Wang X.Y., Eley G., James C.D. 2000. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383–1387.

    PubMed  CAS  Google Scholar 

  21. Fry D.W. 1999. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. 82: 207–218.

    Article  PubMed  CAS  Google Scholar 

  22. Fulci G., Labuhn M. Maier D., et al. 2000. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19:3816–3822.

    Article  PubMed  CAS  Google Scholar 

  23. Gnarra J.R., Zhou S., Merrill M.J., et al. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 93: 10,589–10,594.

    Article  PubMed  CAS  Google Scholar 

  24. Gonzalez-Agosti C., Xu L., Pinney D., et al. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13:1239–1247.

    PubMed  CAS  Google Scholar 

  25. Gu J., Tamura M., Yamada K.M. 1998. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J. Cell. Biol. 143:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  26. Hahn H., Wicking C., Zaphiropoulous P.G., et al. 1996. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841–851.

    Article  PubMed  CAS  Google Scholar 

  27. He J., Allen J.R., Collins V.P., et al. 1994. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:5804–5807.

    PubMed  CAS  Google Scholar 

  28. He J., Olson J.J., James C.D. 1995. Lack of p16INK4 or retinoblastoma protein (pRb) or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55:4833–4836.

    PubMed  CAS  Google Scholar 

  29. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. 1991. p53 mutations in human cancers. Science 253:49–53.

    Article  PubMed  CAS  Google Scholar 

  30. Husemann K., Wolter M., Büschges R., et al. 1999. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 58:1041–1050.

    Article  PubMed  CAS  Google Scholar 

  31. Ichimura K., Schmidt E.E., Goike H.M., Collins V.P. 1996. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065–1072.

    PubMed  CAS  Google Scholar 

  32. Irving R.M., Moffat D.A., Hardy D.G., et al. 1994. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum. Mol. Genet. 3:347–350.

    Article  PubMed  CAS  Google Scholar 

  33. James C.D., Carlbom E., Dumanski J.P., et al. 1988. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 48:5546–5551.

    PubMed  CAS  Google Scholar 

  34. James C.D., Carlbom E., Nordenskjold M., et al. 1989. Mitotic recombination of chromosome 17 in astrocytomas. Proc. Natl. Acad. Sci. USA 86:2858–2862.

    Article  PubMed  CAS  Google Scholar 

  35. James CD, Galanis E, Frederick L, et al. 1999. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int. J. Oncol. 15:547–553.

    PubMed  CAS  Google Scholar 

  36. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. 1994. A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436–440.

    Article  PubMed  CAS  Google Scholar 

  37. Klein G. 1988. Oncogenes and tumor suppressor genes. Acta Oncol. 27:427–437.

    Article  PubMed  CAS  Google Scholar 

  38. Korkolopoulou P., Christodoulou P., Kouzelis K., et al. 1997. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br. J. Cancer 75:1269–1278.

    PubMed  CAS  Google Scholar 

  39. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491–7495.

    Article  PubMed  CAS  Google Scholar 

  40. Kuska B. 1996. Cancer genome anatomy project set for take-off. J. Natl. Cancer Inst. 88: 1801–1803.

    Article  PubMed  CAS  Google Scholar 

  41. Lasko D., Cavenee W., Nordenskjold M. 1991. Loss of consitutional heterozygosity in human cancer. Ann. Rev. Genet. 25:281–314.

    Article  PubMed  CAS  Google Scholar 

  42. Li J., Yen C., Liaw D., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947.

    Article  PubMed  CAS  Google Scholar 

  43. Libermann T.A., Nusbaum H.R., Razon N., et al. 1985. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144–147.

    Article  PubMed  CAS  Google Scholar 

  44. Lin H., Bondy M.L., Langford L.A., et al. 1998. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin. Cancer Res. 4:2447–2454.

    PubMed  CAS  Google Scholar 

  45. Lukas J., Parry D., Aagaard L., et al. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506.

    Article  PubMed  CAS  Google Scholar 

  46. Maehama T., Dixon J.E. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:13,375–13,378.

    Article  PubMed  CAS  Google Scholar 

  47. Malkin D. 1993. p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. 66:83–92.

    Article  PubMed  CAS  Google Scholar 

  48. Mao L., Merlo A., Bedi G., et al. 1995. A novel p16INK4A transcript. Cancer Res. 55: 2995–2997.

    PubMed  CAS  Google Scholar 

  49. Martin G.A., Viskochil D., Bollag G., et al. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843–849.

    Article  PubMed  CAS  Google Scholar 

  50. Myers M.P., Stolarov J.P., Eng C., et al. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dualspecificity phosphatase. Proc. Natl. Acad. Sci. USA 94:9052–9057.

    Article  PubMed  CAS  Google Scholar 

  51. Nagane M., Levitzki A., Gazit A., et al. 1998. Drug resistance of human glioblastoma cells conferred by a tumorspecific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95:5724–5729.

    Article  PubMed  CAS  Google Scholar 

  52. Neshat M.S., Mellinghoff I.K., Tran C., et al. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10,314–10,319.

    Article  PubMed  CAS  Google Scholar 

  53. Nishikawa R., Furnari F.B., Lin H., et al. 1995. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res. 55:1941–1945.

    PubMed  CAS  Google Scholar 

  54. Nishikawa R., Ji X.D., Harmon R.C., et al. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 91:7727–7731.

    Article  PubMed  CAS  Google Scholar 

  55. Ng H.K., Lam P.Y. 1998. The molecular genetics of central nervous system tumors. Pathology 30:196–202.

    Article  PubMed  CAS  Google Scholar 

  56. Nobori T., Miura K., Wu D.J., Lois A, et al. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756.

    Article  PubMed  CAS  Google Scholar 

  57. Oliner J.D. Pietenpol J.A., Thiagalingam S., et al. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857–860.

    Article  PubMed  CAS  Google Scholar 

  58. Olson J.J., Barnett D., Yang J., et al. 1998. Gene amplification as a prognostic factor in primary brain tumors. Clin. Cancer Res. 4:215–222.

    PubMed  CAS  Google Scholar 

  59. Peters G. 1994. The D-type cyclins and their role in tumorigenesis. J. Cell. Sci. Suppl. 18: 89–96.

    PubMed  CAS  Google Scholar 

  60. Podsypanina K., Lee R.T., Politis C., et al. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl. Acad. Sci. USA 98:10,320–10,325.

    Article  PubMed  CAS  Google Scholar 

  61. Pollack I.F., Mulvihill J.J. 1997. Neurofibromatosis 1 and 2. Brain Pathol. 7:823–836.

    Article  PubMed  CAS  Google Scholar 

  62. Pomerantz J., Schreiber-Agus N., Liegeois N.J., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723.

    Article  PubMed  CAS  Google Scholar 

  63. Raffel C., Frederick L., O’Fallon J.R., et al. 1999. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin. Cancer Res. 5:4085–4090.

    PubMed  CAS  Google Scholar 

  64. Raffel C., Gilles F.E., Weinberg K.I.. 1990. Reduction to homozygosity and gene amplification in central nervous system primitive neuroectodermal tumors of childhood. Cancer Res. 50:587–591.

    PubMed  CAS  Google Scholar 

  65. Raffel C., Jenkins R.B., Frederick L., et al. 1997. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 57:842–845.

    PubMed  CAS  Google Scholar 

  66. Reifenberger G., Liu L., Ichimura K., et al. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736–2739.

    PubMed  CAS  Google Scholar 

  67. Reifenberger G., Reifenberger J., Ichimura K., et al. 1994. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 54:4299–4303.

    PubMed  CAS  Google Scholar 

  68. Reifenberger J., Reifenberger G., Liu L., et al. 1994. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145:1175–1190.

    PubMed  CAS  Google Scholar 

  69. Reifenberger J., Wolter M., Weber R.G., et al. 1998. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58: 1798–1803.

    PubMed  CAS  Google Scholar 

  70. Rosenberg J.E., Lisle D.K., Burwick J.A., et al. 1996. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483–2485.

    PubMed  CAS  Google Scholar 

  71. Sainz J., Huynh D.P., Figueroa K., et al. 1994. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum. Mol. Genet. 3:885–891.

    Article  PubMed  CAS  Google Scholar 

  72. Sausville E.A., Zaharevitz D., Gussio R., et al. 1999. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 82:285–292.

    Article  PubMed  CAS  Google Scholar 

  73. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:6321–6324.

    PubMed  CAS  Google Scholar 

  74. Schrock E., du Manoir S., Veldman T., et al. 1996. Multicolor spectral karyotyping of human chromosomes. Science 273:494–497.

    Article  PubMed  CAS  Google Scholar 

  75. Serrano M., Hannon G.J., Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707.

    Article  PubMed  CAS  Google Scholar 

  76. Sherr CJ. 1995. D-type cyclins. Trends Biochem. Sci. 20:187–190.

    Article  PubMed  CAS  Google Scholar 

  77. Shiohara M., el-Deiry W.S., Wada M., et al. 1994. Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781–3784.

    PubMed  CAS  Google Scholar 

  78. Simmons M.L., Lamborn K.R., Takahashi M., et al. 2001. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 61:1122–1128.

    PubMed  CAS  Google Scholar 

  79. Smith J.S., Alderete B., Minn Y., et al. 1999. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152.

    Article  PubMed  CAS  Google Scholar 

  80. Smith J.S., Perry A., Borell T.J., et al. 2000. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18: 636–645.

    PubMed  CAS  Google Scholar 

  81. Smith J.S., Tachibana I., Passe S.M., et al. 2001. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Nat. Cancer Inst. 93:1246–1256.

    Article  PubMed  CAS  Google Scholar 

  82. Smith J.S., Wang X.Y., Qian J., et al. 2000. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol. 59:495–503.

    PubMed  CAS  Google Scholar 

  83. Southern EM. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503–517.

    Article  PubMed  CAS  Google Scholar 

  84. Snijders A.M., Nowak N., Segraves R., et al. 2001. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat. Genet. 29:263–264.

    Article  PubMed  CAS  Google Scholar 

  85. Steck P.A., Pershouse M.A., Jasser S.A., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356–362.

    Article  PubMed  CAS  Google Scholar 

  86. Tada M., Matsumoto R., Iggo R.D., et al. 1998. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 58:1793–1797.

    PubMed  CAS  Google Scholar 

  87. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614–1617.

    Article  PubMed  CAS  Google Scholar 

  88. Tse J.Y., Wong J.H., Lo K.W., et al. 1997. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am. J. Clin. Pathol. 107: 459–466.

    PubMed  CAS  Google Scholar 

  89. Ueki K. Ono Y., Henson J.W., et al. 1996. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56:150–153.

    PubMed  CAS  Google Scholar 

  90. von Deimling A., Louis D.N., Menon A.G. et al. 1993. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol. 86:81–85.

    Article  Google Scholar 

  91. von Deimling A., Louis D.N., von Ammon K., et al. 1992. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res. 52: 4277–4279.

    Google Scholar 

  92. Waha A., Baumann A., Wolf H.K., et al. 1996. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J. Neurosurg. 85:634–641.

    Article  PubMed  CAS  Google Scholar 

  93. Wang S.I., Puc J., Li J., et al. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57:4183–4186.

    PubMed  CAS  Google Scholar 

  94. Wasson J.C., Saylors R.L. III, Zeltzer P., et al. 1990. Oncogene amplification in pediatric brain tumors. Cancer Res. 50:2987–2990.

    PubMed  CAS  Google Scholar 

  95. Watanabe K., Tachibana O., Sata K., et al. 1996. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6:217–223.

    Article  PubMed  CAS  Google Scholar 

  96. White R, Lalouel JM. 1988. Chromosome mapping with DNA markers. Sci. Am. 258:40–48.

    Article  PubMed  CAS  Google Scholar 

  97. Wolter M., Reifenberger J., Sommer C, et al. 1997. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 57:2581–2585.

    PubMed  CAS  Google Scholar 

  98. Wong A.J., Bigner S.H., Bigner D.D., et al. 1987. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA 84:6899–6903.

    Article  PubMed  CAS  Google Scholar 

  99. Yahamada A.M., Bruner J.M., Donehower L.A., Morrison R.S. 1995. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol. Cell. Biol. 15: 4249–4259.

    Google Scholar 

  100. Zurawel R.H., Chiappa S.A., Allen C., Raffel C. 1998. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 58:896–899.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Pathology, Mayo Clinic and Medical School, Rochester, MN

    C. David James PhD

Authors
  1. C. David James PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Duke University Medical Center, Durham, NC

    Francis Ali-Osman DSc

  2. Comprehensive Cancer Center, Duke University Medical Center, Durham, NC

    Francis Ali-Osman DSc

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

James, C.D. (2005). Molecular Genetics of Tumors of the Central Nervous System. In: Ali-Osman, F. (eds) Brain Tumors. Contemporary Cancer Research. Humana Press. https://doi.org/10.1385/1-59259-843-9:019

Download citation

Publish with us

Policies and ethics

Search

Navigation